- Home
- INVE vs IMUX Comparison
INVE vs IMUX Comparison
Compare INVE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | IMUX |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 85.8M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVE | IMUX |
|---|---|---|
| Price | $3.49 | $0.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.50 | ★ $6.00 |
| AVG Volume (30 Days) | 37.0K | ★ 1.5M |
| Earning Date | 11-10-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.52 |
| 52 Week High | $4.07 | $1.39 |
Technical Indicators
Market Signals| Indicator | INVE | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 29.04 |
| Support Level | $3.23 | $0.55 |
| Resistance Level | $3.70 | $0.60 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 51.57 | 1.09 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.